AstraZeneca has made its third big deal with a huge corporation this week, this time a $700 million cancer drug deal with Inovio.

The company is roaring to go with its sole rights over an immune boosting medicine that it bought from Inovio. And as their down payment, Inovio gets $27.5 million aiming at closing up the $700 million total amount due, according to The Market Business.

The success hangs in the balance and strongly depends on the INO-3112 drug that is gunning to eradicate HPV types 16 and 18.

The research team at AstraZeneca is studying the drug along with the analysis of other immune therapy drug options. As of today, the INO-3112 drug is in the first and second phases of its clinical trials.

AstraZeneca is not the only player in the game. In order to stay a step ahead of the pack, they will have to aggressively continue to provide results.

Cancer has pushed mankind to limits they knew they never had in an attempt to find a cure for the fatal malady. The style of metastasis of the disease unfortunately does not offer a rational analysis or prediction.

Experts have for decade prodded at the disease from multiple angles with alternative medicines, chemotherapy and radiotherapy. But, the disease keeps on ticking and running rampant in what we consider a developed world full of cures and solutions.

Other deals AstraZeneca has signed will also benefit cancer treatment in a big way. All of these drugs and the ones proposed for the future are set against stopping cancer dead in its tracks, what seems to be the only way to stop it.

In other hopes, scientists hope to develop a vaccine in the future for cancer. Experts recognize cancer as a disease of civilization, like depression, obesity and appendicitis and the only way to eradicate them is through continuous years of non-stop research.